Medicine 📍 UA

РІАЛТРІС МОНО

306,41 ₴

Price from pharmacies (Compendium)

Analogs of РІАЛТРІС МОНО

Find cheaper analogs and generic equivalents for РІАЛТРІС МОНО.

Ingredients

Active Ingredient: mometasone

Product Overview

About RIALTRIS MONO

RIALTRIS MONO contains mometasone furoate, a synthetic corticosteroid for topical use with a pronounced anti-inflammatory effect.

Composition

Active substance: mometasone furoate. One dose contains mometasone furoate monohydrate in an amount equivalent to 50 mcg of mometasone furoate. Excipients: microcrystalline cellulose and carboxymethylcellulose sodium, glycerol, citric acid monohydrate, sodium citrate, polysorbate 80, benzalkonium chloride, water for injections.

Indications

The drug is used for the treatment of seasonal or perennial allergic rhinitis in adults and children aged 3 years and older. Prophylactic treatment of moderate to severe allergic rhinitis is recommended to be started 4 weeks before the expected start of the pollen season. As an adjunct, it is used during antibiotic treatment of acute episodes of sinusitis in adults, including elderly patients, and children aged 12 years and older.

RIALTRIS MONO is also indicated for the treatment of symptoms of acute rhinosinusitis without signs of severe bacterial infection in adults and children aged 12 years and older. Treatment of nasal polyps and associated symptoms, including nasal congestion and loss of smell, is used in patients aged 18 years and older.

Pharmacological properties

Mometasone furoate exerts a local anti-inflammatory effect at doses that do not cause systemic effects. Its anti-inflammatory and anti-allergic action is primarily associated with the inhibition of the release of mediators of allergic reactions. The substance significantly reduces the synthesis and release of leukotrienes from the leukocytes of patients with allergic diseases.

In cell culture studies, mometasone furoate demonstrated 10 times higher activity than beclomethasone dipropionate, betamethasone, hydrocortisone, and dexamethasone in inhibiting the synthesis and release of IL-1, IL-5, IL-6, and TNFα. It is also a potent inhibitor of the production of Th2-cytokines IL-4 and IL-5 from human CD4+ T-cells.

Source: Compendium